Genmab AS Ownership

GMAB Stock  DKK 1,479  4.50  0.30%   
Genmab AS has a total of 65.96 Million outstanding shares. 30% of Genmab AS outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Genmab AS in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Genmab AS, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.

Genmab Stock Ownership Analysis

About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.19. Genmab AS recorded earning per share (EPS) of 83.21. The entity had not issued any dividends in recent years. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark. To learn more about Genmab AS call Jan Winkel at (45) 70 20 27 29 or check out www.genmab.com.

Genmab AS Outstanding Bonds

Genmab AS issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genmab AS uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genmab bonds can be classified according to their maturity, which is the date when Genmab AS has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with Genmab AS

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genmab AS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will appreciate offsetting losses from the drop in the long position's value.

Moving together with Genmab Stock

  0.93NOVO-B Novo Nordisk ASPairCorr
  0.81ALK-B ALK Abell ASPairCorr
  0.88BAVA Bavarian NordicPairCorr
  0.71ZEAL Zealand Pharma ASPairCorr

Moving against Genmab Stock

  0.69MAERSK-B AP MllerPairCorr
  0.67MAERSK-A AP MllerPairCorr
  0.48ORPHA Orphazyme ASPairCorr
  0.36CHEMM ChemoMetec ASPairCorr
The ability to find closely correlated positions to Genmab AS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genmab AS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genmab AS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genmab AS to buy it.
The correlation of Genmab AS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genmab AS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genmab AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genmab AS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Information and Resources on Investing in Genmab Stock

When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.